Iowa Law Eliminates Prior Authorizations for Cancer Screenings and Emergency Care
In Iowa, a groundbreaking new law signed by Governor Kim Reynolds eliminates the need for prior authorizations from health insurance companies for cancer screenings and emergency care. This legislative change, outlined in House File 2635, aims to streamline access to necessary health services by removing administrative hurdles that can delay treatment.
Health care providers often find the prior authorization processes burdensome, as they require submitting requests to insurers to determine coverage eligibility for various medical services, including medications and specialist referrals. Dr. Wendy Woods-Swafford, chief medical officer at UnityPoint Health, stated that managing these authorizations necessitates significant additional time weekly, impacting both her and her staff's availability for patient care. Despite frequent approvals on appeal, the time taken to secure such approvals is considered excessive.
Representative Austin Harris emphasized that existing prior authorization requirements act as bureaucratic impediments, potentially delaying care delivery by several weeks. Some insurers, such as Wellmark Blue Cross and Blue Shield, already avoid requiring prior authorizations for certain services, including emergency care and some cancer-related procedures.
The Federation of Iowa Insurers supports this legislative change, aligning with guidelines set by the National Comprehensive Cancer Network for screenings and treatments without prior authorization requirements. During discussions for the bill, concerns were raised about the administrative workload leading to physician burnout and the potential impact on recruitment. Healthcare professionals from organizations such as the University of Iowa and MercyOne suggest that reducing paperwork might attract more doctors to practice in Iowa, a state currently experiencing a provider shortage.
One notable aspect of the law requires that insurance reviews be conducted by health professionals with expertise in the relevant medical specialty. This shift aims to improve decision-making quality by ensuring reviewers understand the specifics of the recommended treatments, which Dr. Woods-Swafford believes will enhance the approval process. The new law, effective January 1, also addresses the role of artificial intelligence in review procedures, mandating human involvement in decision-making rather than relying solely on algorithms.
However, Dr. Woods-Swafford advocates for further legislation that includes pharmacy professionals in the review process of prescribed medications, recognizing that insurance denials can also occur in pharmaceutical contexts. She stresses the importance of maintaining patient-centric perspectives in efforts to enhance healthcare system efficiency, noting that delays in authorizations, sometimes lasting up to four weeks, could be detrimental to timely medical treatment.